Abstract | OBJECTIVE: STUDY DESIGN: RESULT: For 184 doses, occurrence rates of transient bradycardia (13) and plugged endotracheal tube (5) were low, and no other adverse effects were noted. Treatment transiently improved the respiratory severity score (FiO(2) × mean airway pressure), SP-B content (+75%) and surface properties of isolated surfactant. Levels of eight proinflammatory cytokines in tracheal aspirate were interrelated and unchanged from baseline after surfactant treatment. CONCLUSION: Booster doses of surfactant for premature infants with lung disease are safe and transiently improve respiratory status as well as composition and function of endogenous surfactant.
|
Authors | J D Merrill, P L Ballard, S E Courtney, D J Durand, A Hamvas, A M Hibbs, K W Lu, R M Ryan, A M Reynolds, K Spence, R H Steinhorn, W E Truog, E C Eichenwald, R A Ballard |
Journal | Journal of perinatology : official journal of the California Perinatal Association
(J Perinatol)
Vol. 31
Issue 9
Pg. 599-606
(Sep 2011)
ISSN: 1476-5543 [Electronic] United States |
PMID | 21311500
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Bronchopulmonary Dysplasia
(drug therapy, therapy)
- Female
- Humans
- Infant, Newborn
- Infant, Premature
- Male
- Pilot Projects
- Pulmonary Surfactants
(administration & dosage)
- Respiration, Artificial
- Treatment Outcome
|